Asthma: increased risk for severe pneumonia with inhaled corticosteroids

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.
Takeaway
  • In patients with asthma, current ICS use was associated with significantly increased risk of being hospitalized for pneumonia, especially with doses ≥500 µg of fluticasone-equivalent per day. 
  • The risk associated with budesonide (Pulmicort) and fluticasone (Flixotide) were similar.

Why this matters

  • It is known that ICS use increases risk for pneumonia in COPD, but findings in patients with asthma have been contradictory.
  • The present findings disagree with the conclusions of the only other study that directly assessed ICS and pneumonia risk in asthma. 
  • The finding of similar risk with budesonide and fluticasone conflict with previous findings of a higher risk with fluticasone.

Study design

  • Retrospective cohort study evaluated 152,412 patients with asthma between 1990 and 2007.
  • Funding: None.

Key results

  • 1928 patients had pneumonia during mean follow-up duration of 4.8 y.
  • Current ICS use was associated with 83% increased rate of hospitalizations due to pneumonia, dose equivalent to ≥500 mg fluticasone increased the risk by 96%.
  • Risk for pneumonia increased with use of budesonide (relative risk [RR], 2.67; 95% CI, 2.05-3.49), fluticasone (RR, 1.93; 95% CI, 1.58-2.36), but not with other ICS groups (RR, 1.23; 95% CI, 0.92-1.63).

Limitations

  • Data on smoking and other environmental exposures were not available.